Skip to content
lifestyle.careersavvy.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Candel Therapeutics
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 9, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2026
Candel Therapeutics Announces Pricing of Public Offering
February 21, 2026
Candel Therapeutics Announces Proposed $100 Million Public Offering
February 21, 2026
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
February 21, 2026
←
Previous Page
1
2
3